恶性风险指数对绝经期卵巢囊性及囊实性肿瘤评估的价值

Malignant risk index in evaluation of menopausal ovarian cystic and cystic-solid tumors

对2013年5月至2017年5月首都医科大学附属北京妇产医院行手术治疗的349例绝经后卵巢囊性及囊实性肿瘤患者的临床资料进行回顾性分析,其中术后病理诊断为恶性肿瘤者100例、良性肿瘤者228例、交界性肿瘤者21例。根据术前盆腔超声及血清CA125检查资料行恶性风险指数(RMI)评分,以200分为阈值,<200分者为良性,>200分者恶性,与术后病理结果对比进行分析。RMI评价卵巢囊性及囊实性肿瘤良、恶性的敏感度为0.840(84/100)、特异度0.987(225/228)、正确率94.2%(309/328),误诊率1.3%(3/228),漏诊率16.0%(16/100)。RMI评分系统与病理学诊断一致性检验的Kappa=0.858(P<0.05)。提示RMI对于绝经后卵巢肿瘤的良、恶性评估可信度较高。

Clinical data of 349 patients with postmenopausal ovarian cystic and cystic solid tumors undergoing surgical treatment in Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University from May 2013 to May 2017 were retrospectively analyzed.Postoperative pathology confirmed 100 cases of malignant tumor,228 cases of benign tumor,and 21 cases of borderline tumor.The malignant risk index(RMI)score was calculated based on the preoperative pelvic ultrasound and serum CA125 level,and the score<200 was classified as benign tumors and≥200 as malignant tumors.The postoperative pathological results were used as gold standard,the sensitivity,specificity,accurate rate of RMI in diagnosis of malignant tumors was 0.840(84/100),0.987(225/228)and 94.2%(309/328),respectively.The consistency of RMI with pathological diagnosis was high(Kappa=0.858,P<0.05).The study suggests that RMI has a high degree of credibility for the evaluation of postmenopausal ovarian cystic and cystic solid tumors.